068760.KQ
Celltrion Pharm, Inc.
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 40,850.00
−0.73%Year over year
Reported trailing growth
- Revenue
- +13.9%
- EBITDA
- -11.1%
- EBIT
- +23.2%
- EPS
- +29.6%
- Free cash flow
- -58.7%
- Operating cash flow
- -41.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +11.6%
- EBITDA
- +13.2%
- EBIT
- +13.7%
- Net income
- +14.3%
- EPS
- +15.1%
- Free cash flow
- +35.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026